Navigation Links
New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
Date:4/16/2010

Vienna, Austria, Thursday 15 April: Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine (ALT) and aspartate aminotransferases (AST), hepatic enzymes that indicate cell damage.

GS-9450, a potent inhibitor of caspases-8, -9 and -1, the intra-cellular proteins that initiate programmed cell death (or cell suicide, also known as apoptosis) in damaged cells, is a potential new treatment option for patients with NASH a disease characterised by fat build-up in liver cells with subsequent inflammation resulting in accumulation of scar tissue (fibrosis), cirrhosis and eventual liver failure.

Professor Fabio Marra of the EASL scientific committee commented: "It is encouraging to see that GS-9450-associated reduction of apoptosis and cell damage seen in animal models has translated to a significant patient population, and seems to be consistent with a good tolerability profile in patients from a variety of countries. Further studies are needed to evaluate the action of this therapy on histology and to confirm the drug's efficacy and safety in larger patient populations."

In this double-blind, parallel-group study, patients (n=124, principally male, mean age 45 years, with Body Mass Index (BMI) of >30kg/m2) with biopsy-proven NASH were randomised to receive 1, 5, 10 or 40mg GS-9450 or placebo once daily for 4 weeks. After 4 weeks on treatment, patients in the 40mg treatment group experienced the greatest reduction in ALT and AST levels.

At week four, linear regression of ALT versus GS-9450 dose was highly significant (p<0.0001) with 35% achieving ALT levels within the normal range (7-56 U/L ) compared to 0% at study baseline, and 48% achiev
'/>"/>

Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Source:Eurekalert

Page: 1 2

Related medicine news :

1. NASA selects DNA Medicine Institutes Nanoscale Diagnostics Technology for Phase II SBIR
2. PRA International Rolls out Client Access to Oracle(R) RDC for Early Phase Studies
3. Treatment for chronic hepatitis C: A phase II study
4. New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology
5. InstaMed Achieves Core Phase II Certification to Streamline Provider Access to Consistent Electronic Eligibility and Claim Status
6. Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765
7. Aetna and WellPoint Achieve CORE Phase II Certification
8. Data from Phase 1 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Non-Hodgkins Lymphoma
9. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
10. Hepregen Corporation Receives SBIR Phase II Grant from the National Science Foundation and Presents Corporate Update at OneMed Forum
11. Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2 September 2014: A simple awareness campaign in general ... to research presented at ESC Congress today by Professor ... fibrillation (AF) is the most common cardiac arrhythmia. It ... and the risk of stroke risk by five-fold. Similarly, ... 4 cases. However, AF is often overlooked and diagnosed ...
(Date:9/2/2014)... 02, 2014 Aeroflow Healthcare, an industry ... Southeast, announced the opening of its new office to ... is: 310 Business Parkway, Suite D, Greer, SC 29651. ... patients with a more convenient location in the Greenville ... Healthcare and the physicians, hospitals and patients we serve, ...
(Date:9/2/2014)... New York, NY (PRWEB) September 02, 2014 ... for women are long gone. But even though men shave ... an unhealthy appearance – rough and irritated skin isn’t inevitable, ... Advanced Dermatology P.C. , For decades, skin care ... years have witnessed a surge in men of all ages ...
(Date:9/1/2014)... web hosting provides a Windows based server environment. There ... and the new demand has resulted in an increase ... a variety of different services at very affordable prices. ... web hosting suppliers from the USA and announced that ... webmasters who want to buy high quality WordPress hosting ...
(Date:9/1/2014)... September 02, 2014 NAPW ... Manager at Gibson Orthopedics Pain Treatment & ... Year. Ms. Brinkley is recognized with this prestigious ... largest, most-recognized networking organization of women in the ... National Association of Professional Women is a powerfully ...
Breaking Medicine News(10 mins):Health News:Simple awareness campaign in general practice identifies new cases of AF 2Health News:Aeroflow Healthcare Opens Office In Greer, SC To Service Greenville & Spartanburg Patients 2Health News:Rough Isn’t Rugged in Men’s Skin: Dermatology specialist Dr. Joshua Fox with Advanced Dermatology PC offers tips on easy skin maintenance for men 2Health News:Rough Isn’t Rugged in Men’s Skin: Dermatology specialist Dr. Joshua Fox with Advanced Dermatology PC offers tips on easy skin maintenance for men 3Health News:SEO Hosting Review Site Top10BestSEOHosting.com: Best Windows Web Hosting Suppliers From the USA Now Unveiled 2Health News:National Association of Professional Women Announces Laura Brinkley, Manager, Gibson Orthopedics Pain Treatment & Cardiology Clinic, a 2014 Professional Woman of the Year 2
... ROCHESTER, Minn. -- New Mayo Clinic research studied the ... and found that routine annual evaluation of prostate growth ... prostate cancer. However the study suggests that if a ... is reasonable to determine if he has prostate cancer. ...
... ... a high potency, animal free and consistent alternative to chicken lysozyme, which is used ... than chicken lysozyme and increases protein yield from bacterial fermentation. , ... Fort Collins, CO (PRWEB) November 10, ...
... from Wingate Healthcare outlines SHRM,s voluntary paid leave principles ... In testimony today before the Senate Health, Education, Labor ... SPHR, vice president of human resources for Wingate Healthcare, ... workplace leave that reflect the needs of today,s workforce. ...
... This release is available in Spanish . , A ... a higher presence of the parasite Anisakis spp in anchovies ... and they insist on freezing or cooking fish before consuming it. ... to freeze the hours at -20 C", say the UGR ...
... D. Eilers Professor of Medicine and Health Care Management and ... the Wharton School, was presented with the Alpha Omega Alpha ... of Medical Colleges (AAMC). The award was presented on ... Recognizing Dr. Asch, the AAMC said, "Dr. ...
... Study in mice finds anti-inflammatories don,t help those with ... Taking nonsteroidal anti-inflammatory drugs (NSAIDs) from a young age ... the results of a new study in mice. , ... cycle events (CCEs) occurs early in the development of ...
Cached Medicine News:Health News:Routine evaluation of prostate size not as effective in cancer screening, Mayo study finds 2Health News:InVitria Reports Expanded Manufacturing Capability to Meet Commercial Demand for Lysobac, an Animal Free Reagent for Bacterial Fermentation 2Health News:SHRM Testifies before Senate on H1N1 and Need for Flexible Paid Leave Policies 2Health News:SHRM Testifies before Senate on H1N1 and Need for Flexible Paid Leave Policies 3Health News:Anisakiasis hazard varies depending on the origin of the fish, according to a study 2Health News:David A. Asch, M.D., M.B.A., receives AAMC Distinguished Teacher Award 2
(Date:8/30/2014)... 30, 2014  Boston Scientific has released the ... foR Heart Failure (NECTAR-HF) clinical trial, the first ... nerve stimulation (VNS) for the treatment of heart ... Therapeutics and Cardiology and Director of the Clinical ... Sante et de la Recherche Medicale presented the ...
(Date:8/29/2014)... DALLAS , Aug. 29, 2014 /PRNewswire-iReach/ -- ... Crystallography Scanner Industry, 2009-2019 is a professional and ... X-Ray Crystallography Scanner industry . The report firstly ... including its classification, application and manufacturing technology. The ... of X-Ray Crystallography Scanner listing their product specification, ...
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... (KOLs) can be the difference between a product,s success ... effectively map and stratify KOL targets – and then ... the type of strong relationships upon which successful KOL ... savvy pharma companies have identified internal inconsistencies in their ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5Implementing a Strategic Thought Leader Management & Engagement System 2
... LOUIS, April 7, 2011 A study ... Ascension Health, the nation,s third-largest health system, has achieved ... rates, reducing bed sores and keeping patients safe.  In ... preventable injuries and deaths. Ascension Health has seen consistent ...
... ROANOKE, Va., April 7, 2011 PixelOptics ... company, announced today the successful closing of a ... (NYSE: SFE).  The financing is comprised of ... venture capital organizations include: Safeguard Scientifics, Delphi Ventures, ...
Cached Medicine Technology:Study Highlights Successes of Ascension Health Quality Initiative 2PixelOptics Closes $45 Million Financing 2PixelOptics Closes $45 Million Financing 3PixelOptics Closes $45 Million Financing 4
... Graham-Field has been developing ... than 58 years. Our medical-surgical ... reputation for innovation, quality and ... brands include the Labtron® line ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... held at angles up to 45° without sacrificing ... column, finger grooves for a non-slip gripping surface, ... of regular oxygen tubing. The large diffuser ... sustain optimum mist concentration at every setting. ...
... and Respiratory Products, ,Westmed designs, manufacturers ... Anesthesia and Respiratory professionals. Our mission is ... the clinician's ability to deliver quality medical ... bottom line. , ,Our web site ...
Medicine Products: